The invention relates to a unique formulation for brain health. The formulation includes a mixture of CBD and THC and/or flavonoids, along with at least one antioxidant, and preferably an emulsifier, spearmint extract and a film-forming agent. The formulation improves memory and cognition as well as prevents and improves symptoms in dementia and related diseases related to deterioration or loss of memory and/or cognition.

The invention relates to a unique formulation for brain health. The formulation includes a mixture of CBD and THC and/or flavonoids, along with at least one antioxidant, and preferably an emulsifier, spearmint extract and a film-forming agent. The formulation improves memory and cognition as well as prevents and improves symptoms in dementia and related diseases related to deterioration or loss of memory and/or cognition.

Compositions and methods can use a combination of an autophagy inducer, such as spermidine, and high protein for induction of autophagy in an individual in need thereof. Preferably, a formulation containing a combination of an autophagy inducer and high protein is administered to the individual in an amount effective to induce autophagy, for example in muscle. The formulation can concomitantly promote protein synthesis and removal of damaged cellular materials. The recipient of administration can be a critically ill patient, for example a patient in the Intensive Care Unit (ICU), and/or an ageing patient, for example an elderly individual or an individual with sarcopenia.

Compositions and methods can use a combination of an autophagy inducer, such as spermidine, and high protein for induction of autophagy in an individual in need thereof. Preferably, a formulation containing a combination of an autophagy inducer and high protein is administered to the individual in an amount effective to induce autophagy, for example in muscle. The formulation can concomitantly promote protein synthesis and removal of damaged cellular materials. The recipient of administration can be a critically ill patient, for example a patient in the Intensive Care Unit (ICU), and/or an ageing patient, for example an elderly individual or an individual with sarcopenia.

The present disclosure provides compositions and methods of using one or more of the metabolites spermidine, palmitoylethanolamide (PEA), oleoylethanolamide (OEA), and 1-methylnicotinamide (1-MNA) to induce an anti-inflammatory, anti-oxidant, and/or immuno-modulatory effect in a subject. The compositions and methods described herein can enhance biochemical functionalities relevant to overall health and disease progression, promote longevity and healthspan, and/or delay or inhibit the cellular aging process in the subject.

The present disclosure provides compositions and methods of using one or more of the metabolites spermidine, palmitoylethanolamide (PEA), oleoylethanolamide (OEA), and 1-methylnicotinamide (1-MNA) to induce an anti-inflammatory, anti-oxidant, and/or immuno-modulatory effect in a subject. The compositions and methods described herein can enhance biochemical functionalities relevant to overall health and disease progression, promote longevity and healthspan, and/or delay or inhibit the cellular aging process in the subject.

The present invention relates to compositions comprising spermidine and/or a pharmaceutically acceptable salt thereof for use in the prevention and/or alleviation of side effects caused by nicotinamide, nicotinic acid and/or a pharmaceutically acceptable salt thereof.

The present invention relates to compositions comprising spermidine and/or a pharmaceutically acceptable salt thereof for use in the prevention and/or alleviation of side effects caused by nicotinamide, nicotinic acid and/or a pharmaceutically acceptable salt thereof.

Disclosed herein are polyamine transport inhibitors (PTI) and methods of use as antivirals. Disclosed PTI compounds are useful as treatments for viral infections or can be used as prophylactic agents that protect high risk individuals from becoming infected by the virus. The disclosed PTI compounds can be used alone or in combination with other agents (or other antivirals) to improve patient outcomes such as DFMO (or Remdesivir).

Disclosed herein are polyamine transport inhibitors (PTI) and methods of use as antivirals. Disclosed PTI compounds are useful as treatments for viral infections or can be used as prophylactic agents that protect high risk individuals from becoming infected by the virus. The disclosed PTI compounds can be used alone or in combination with other agents (or other antivirals) to improve patient outcomes such as DFMO (or Remdesivir).